Clinical Trial Update: A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) [Phase 1]

View source ↗

Summary

A Phase 1 trial to assess tolerability of different doses of BI 3820768 in adults with advanced relapsed or refractory germ cell tumors, endometrial cancer, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Germ Cell Tumor
• Ovarian Cancer

Drugs mentioned

• BI 3820768

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer | Phase 1 | Status: RECRUITING